Advertisement
Reform Update: Partisan standoff looms over crucial risk-corridor payments

Reform Update: Partisan standoff looms over crucial risk-corridor payments

By Paul Demko  |  October 24, 2014

A big fight could be brewing over Obamacare's risk-corridor program. Insurers are relying on the program to protect them from major losses if their exchange customers end up being sicker and more costly than anticipated. But Republicans—most notably Sen. Marco Rubio (R-Fla.), a likely 2016...

New hepatitis C drug costs nearly $100,000

By Paul Demko  |  October 11, 2014

A second potential blockbuster drug from Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, it is certain to spark further debate over the pricing of specialty drugs.

Hostile ballot initiatives confront health insurers

By Bob Herman  |  October 11, 2014

Insurance industry officials will gather in Washington this week to discuss the biggest political, legal, legislative and regulatory issues their companies face at the local level.

Consumers using, but confused about, health savings accounts, surveys find

Consumers using, but confused about, health savings accounts, surveys find

By Rachel Landen  |  July 10, 2014

Nearly 17.4 million Americans participate in health savings account-eligible insurance plans, a decade after Congress authorized the creation of health savings accounts, according to results of a census released this week by industry trade group America's Health Insurance Plans.

Insurers urge subsidies for catastrophic plans

Insurers urge subsidies for catastrophic plans

By Rachel Landen  |  June 11, 2014

Insurers are pushing the government to provide financial assistance to people buying what are commonly referred to as catastrophic health plans.

Reform Update: Cost-sharing insurance plans may not be more affordable overall

Reform Update: Cost-sharing insurance plans may not be more affordable overall

By Rachel Landen  |  June 05, 2014

State-based and federally facilitated exchanges are required by the reform law to provide advanced premium tax credits and cost-sharing reductions to low-income plan enrollees. However, a study out this week from consultancy Avalere Health found that insurers' latitude in meeting these requirements...

High drug costs may lead to price controls, AHIP's Ignagni says

High drug costs may lead to price controls, AHIP's Ignagni says

By Paul Demko  |  May 24, 2014

The staggering cost of Sovaldi, the $1,000-a-pill treatment for hepatitis C, is prompting serious discussions among healthcare leaders about the price tags of potentially life-saving specialty drugs and whether the government should regulate those prices.

Excessive drug costs could invite price caps: AHIP's Ignagni

Excessive drug costs could invite price caps: AHIP's Ignagni

By Paul Demko  |  May 21, 2014

The steep cost of Sovaldi—Gilead Sciences' $1,000-per-pill treatment for hepatitis C—is prompting wide-ranging discussions about the cost of drugs and whether the government should take more steps to regulate the cost of potentially life-saving treatments.

Advertisement